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SUMMARY
We previously demonstrated that the deletion of the poly(ADP-ribose)polymerase (Parp)-1 gene
in mice enhances oxidative metabolism, thereby protecting against diet-induced obesity. However,
the therapeutic use of PARP inhibitors to enhance mitochondrial function remains to be explored.
Here, we show tight negative correlation between Parp-1 expression and energy expenditure in
heterogeneous mouse populations, indicating that variations in PARP-1 activity have an impact on
metabolic homeostasis. Notably, these genetic correlations can be translated into pharmacological
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applications. Long-term treatment with PARP inhibitors enhances fitness in mice by increasing the
abundance of mitochondrial respiratory complexes and boosting mitochondrial respiratory
capacity. Furthermore, PARP inhibitors reverse mitochondrial defects in primary myotubes of
obese humans and attenuate genetic defects of mitochondrial metabolism in human fibroblasts and
C. elegans. Overall, our work validates in worm, mouse and human models that PARP inhibition
may be used to treat both genetic and acquired muscle dysfunction linked to defective
mitochondrial function.
INTRODUCTION
Reductions in mitochondrial number and activity are a hallmark of several inherited
mitochondrial diseases, as well as a number of age-related neurodegenerative and metabolic
disorders (Andreux et al., 2013). The sirtuin enzymes have emerged as critical regulators of
mitochondrial and oxidative metabolism (Chalkiadaki and Guarente, 2012). Several studies
have shown that NAD+ levels can be rate-limiting for the deacetylase activity of SIRT1, the
best-characterized sirtuin (Canto and Auwerx, 2012). Boosting intracellular NAD+ levels
has hence become an attractive approach to activate SIRT1 and mitochondrial metabolism.
In line with this, NAD+ availability might even determine circadian shifts in oxidative
capacity (Peek et al., 2013).
One strategy to increase NAD+ levels consists of the inhibition of alternative NAD+
consuming enzymes, such as poly(ADP-ribose) polymerase-1 (PARP-1) (Bai and Canto,
2012), which is involved in DNA damage detection and repair. Upon activation, PARP-1
can deplete intracellular NAD+ levels by 80%. Genetic ablation of Parp-1 increases NAD+
availability and SIRT1 activity in tissues, such as skeletal muscle and brown adipose tissue
(Bai et al., 2011). As a consequence, mitochondrial oxidative capacity is enhanced in muscle
of Parp-1−/− mice, protecting them against high-fat diet (HFD)-induced insulin resistance.
Therefore, PARP inhibition constitutes a plausible strategy to improve metabolic
homeostasis. PARP inhibitors (Paribs) already exist and are clinically tested in the cancer
field (Curtin and Szabo, 2013). The role of PARPs in genome maintenance, however,
questions whether Paribs can be used therapeutically over longer periods of time to prevent
the detrimental metabolic consequences of mitochondrial dysfunction. Here, we demonstrate
that long-term Parib treatment is sustainable and improves mitochondrial function in skeletal
muscle, enhancing endurance performance and protecting against HFD-induced metabolic
complications. We furthermore show that Parp-1 expression is negatively correlated with
energy expenditure in mouse genetic reference populations. Finally, we demonstrate how
acquired and genetic mitochondrial defects can be improved by Paribs. Therefore, our work
sets the stage for the possible clinical use of Paribs in situations of defective mitochondrial
function.
RESULTS AND DISCUSSION
Characterization of Paribs in C2C12 myotubes
We initially compared how different Paribs, BSI-201, PJ-34, ABT-888, AZD-2881 and
MRL-45696, could rescue NAD+ decline upon H2O2-induced PARP-1 activation in
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differentiated mammalian cell lines, such as C2C12 myotubes. MRL-45696, a dual PARP-1
and PARP-2 inhibitor derived from niraparib (Chinnaiyan et al., 2012; Jones et al., 2009)
most efficiently rescued the H2O2-induced NAD+ decline, with a low nanomolar IC50
(Supplemental Table 1). MRL-45696 reduced the redox potential in C2C12 myotubes at
concentrations as low as 1–10nM (Figure S1A), and increased mitochondrial membrane
potential (MMP) (Figure S1B) and O2 consumption rates (OCR) at 10nM (Figure S1C). To
certify that the effects of MRL-45696 are derived from PARP inhibition, we also used
another Parib, AZD-2281 (Olaparib). In agreement, nanomolar concentrations of AZD-2281
decreased redox potential, while increasing MMP and OCR (Figures S1E–S1G). Notably,
MRL-45696 or AZD-2281 were not toxic at these concentrations, as ATP content was
unaffected (Figures S1D and S1H).
Chronic PARP inhibition enhances energy expenditure and SIRT1 activity
As defects in mitochondrial metabolism are a hallmark for many diseases, Paribs could in
principle also be used for these non-oncological indications. However, such use could be
overshadowed by several concerns. First, chronic Parib treatment could induce genomic
instability (Curtin and Szabo, 2013). Second, Paribs would not just affect PARP-1, but also
PARP-2, and the combined reduction of both activities could be detrimental for long-term
viability (Menissier de Murcia et al., 2003). Hence, we characterized the impact of long-
term MRL-45696 treatment in mice. We initially determined that dietary admixture
achieved higher MRL-45696 levels in plasma and muscle than oral gavage (Figures S2A
and S2B), hence choosing this route for further studies.
We next fed HFD admixed with MRL-45696 (50 mg/kg/day) to 10-wk old male C57BL/6J
mice. MRL-45696 blunted HFD-induced body weight gain (Figure 1A) due to reduced fat
accumulation (Figure 1B) and was associated with higher energy expenditure (Figure 1C),
without affecting activity or food intake (Figures 1D and 1E). Although PARP-1 has been
shown to impact genome stability and cell viability, no evidence for toxicity on genomic
DNA or cellular damage was found, as liver 8-oxo-dG and muscle lipid peroxidation levels
were similar between the groups (Figures 1F and 1G). This is in line with the fact that
Parp-1−/− mice are viable and do not show signs of DNA damage unless challenged with
cytotoxic stimuli (de Murcia et al., 1997).
MRL-45696 reduced total PARP activity in skeletal muscle (−50%; Figure 1H) and in others
tissues tested, including brain and liver (Figure S2C). In line with PARP inhibition,
intracellular NAD+ content was higher in muscle from treated mice (Figure 1I). The higher
NAD+ levels were restricted to the nuclear and/or cytosolic compartments, since
mitochondrial NAD+ content was similar between both groups (Figure 1J). Reductions in
PARP activity translated also into SIRT1 activation, as reflected by lower FOXO1
acetylation, despite slightly lowered SIRT1 levels (Figure 1K). Conversely, the unaltered
mitochondrial NAD+ levels did not change SIRT3 activity, as manifested in the acetylation
of Ndufa9 (Figure 1L). These observations are in line with observations in Parp-1−/− mice,
where SIRT1, but not SIRT3, activity was enhanced (Bai et al., 2011).
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PARP inhibition enhances endurance and mitochondrial function
Given that MRL-45696 accumulates and inhibits PARP in the skeletal muscle (Figure 1H
and S2C), we next examined the impact of Paribs on muscle performance and mitochondrial
function in chow-fed mice. Despite similar body weight and composition (Figures S3A–
S3C), MRL-45696-treated mice ran for a significantly longer distance (Figure 2A). Maximal
O2 consumption capacity (VO2max), which critically determines endurance performance,
was significantly higher with MRL-45696 (Figure S3D). As cardiovascular parameters,
including ejection fraction, fractional shortening, ventricular mass and diameter (Figures
S3E–S3I) were unchanged, the higher endurance was most likely due to improved muscle
mitochondrial function. To substantiate this hypothesis, we performed respirometry tests in
permeabilized EDL muscle fibers. Maximal respiration in the coupled state, with electron
input through either complex I alone - using malate, pyruvate and glutamate - or complex I
+II - using, in addition, succinate - was markedly higher in muscles after MRL-45696
(Figure 2B). Maximum electron transport system capacity was also higher after PARP
inhibition, even after the addition of the complex I inhibitor rotenone (Figure 2B). These
results are consistent with the marked increase in citrate synthase (CS) activity after
MRL-45595 (Figure 2C). Finally, Paribs increased oleic acid oxidation rates by ~50%
(Figure 2D). Mitochondrial DNA abundance was, however, not changed (Figure 2E),
suggesting that MRL-45696 does not influence muscle mitochondrial function by increasing
mitochondrial number.
Histological analysis further certified that Paribs enhanced the oxidative profile of skeletal
muscle, as testified by more intense cytochrome c oxidase and succinate dehydrogenase
staining in gastrocnemius (Figure 2F). Remarkably, an increase in slow oxidative MHCI, a
marker for type I fibers, was observed, whereas MHCIIb levels, a type II fiber marker, were
decreased by MRL-45696 (Figure 2G). Furthermore, MHCI staining of gastrocnemius
confirmed the higher type I fiber content after MRL-45696 (Figure 2H). The higher
oxidative capacity after Paribs was accompanied by increased insulin sensitivity, as reflected
by the higher glucose infusion rate during a hyperinsulinemic-euglycemic clamp (Figure
S3J).
We next evaluated the possible contribution of SIRT1 in mediating the effects of Paribs by
using a muscle-specific SIRT1 deficient mouse line (SIRT1skm−/− mice). In line with
previous reports (Menzies et al., 2013; Philp et al., 2011), endurance or VO2max was not
impaired in SIRT1skm−/− mice (data not shown). Interestingly, Paribs were unable to
enhance endurance, respiratory capacity and CS activity in the SIRT1skm−/− mice (Figures
2A–2C). Of note, the expression of Sirt1, Tfam and c-myc was also increased in Parib
treated muscles (Figure S3K), which indicates that a recently identified SIRT1-dependent
pathway (Gomes et al., 2013) by which NAD+ controls metabolic health might also be at
play. Therefore, SIRT1 seems key to the actions of Paribs on muscle metabolism.
MRL-45696 enhances mitochondrial protein translation and triggers the UPRmt
Paribs increase mitochondrial respiratory capacity in worms by triggering the mitochondrial
unfolded protein response (UPRmt-) in a SIRT1-dependent manner (Mouchiroud et al.,
2013). However, the possible translation of this finding into mammals has not been
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explored. We therefore performed blue native page analyses of mitochondrial complexes in
muscles. MRL-45696 increased the abundance of mitochondrial complexes, but did not
change their mobility (Figure 3A). Therefore, increased respiratory chain complex content,
rather than changes in complex composition or stoichiometry, accounts for the enhanced
mitochondrial function. This effect was also observed in cultured mouse embryonic
fibroblast (MEFs) (Figure S4A). As MRL-45696 did not affect mRNA levels of
mitochondrial complex subunits (Figure S4B), we speculated that the higher respiratory
complex content could be due to enhanced mitochondrial protein translation. In line with
this hypothesis, MRL-45696 specifically increased mitochondrial, but not cytosolic (Figures
3B–3D), protein translation rates in MEFs.
Increased mitochondrial translation, without according changes in cytosolic translation rates,
can lead to mitonuclear protein imbalance (Houtkooper et al., 2013), which was evidenced
by altered protein ratios between MTCO1, which is encoded by mtDNA, and SDHA,
encoded by nDNA, induced by MRL-45696 (Figures 3E and 3F). Such a mitonuclear
protein imbalance could trigger UPRmt to restore optimal mitochondrial function
(Houtkooper et al., 2013). In line with this premise, ClpP and Hsp60 levels, which reflect
the presence of UPRmt, were increased in MRL-45696 treated muscles (Figures 3E and 3F).
Altogether, these results illustrate the robust effects of MRL-45696 on mitochondrial
translation, which culminate in the induction of UPRmt. While it is not clear how Paribs
trigger mitonuclear imbalance and UPRmt in mammalian cells, results obtained in C2C12
cells suggest that SIRT1 is required for such an effect (Figure S4C), consistent with the
mechanisms reported in worms (Mouchiroud et al., 2013). In addition, PARPs have been
reported to silence translation during stress by binding and/or PARylating RNA-binding
proteins that control the polyadenylation of mRNAs and protein translation rates (for review,
see (Luo and Kraus, 2012)). Hence, the inhibition of PARP actions on translational
processes could be a complementary mechanism to explain the induction of UPRmt.
Parp-1 expression negatively correlates with energy expenditure
Given the effects of Paribs on mitochondrial function in the C57BL/6J mouse strain, we next
aimed to elucidate whether Parp-1 could determine energy expenditure and oxidative
capacity in genetically complex mouse populations such as the BXD mouse genetic
population (Peirce et al., 2004). Parp-1 expression varied 1.3-fold in skeletal muscle of the
BXD strains, enabling the study of gene expression correlations (Figure 4A). These changes
in Parp-1 expression are not related to natural variations in fiber type composition, as
Parp-1 expression is comparable in muscles having different fiber type content, such as
gastrocnemius or soleus (data not shown). Parp-1 expression in muscles of the BXDs strains
was negatively correlated with night VO2, VO2max improvement after 10 days training and
with expression of the troponin I type 1 slow-twitch muscle isoform (Tnni1) (Figure 4B). In
contrast, Parp-1 positively correlated with body weight, troponin C type 2 fast-twitch
muscle isoform (Tnnc2) and troponin I type 2 fast-twitch muscle isoform (Tnni2) (Figure
4B). This robust genetic correlation suggests a physiological influence of PARP-1 activity
on oxidative metabolism. Indeed, previous results indicated that PARP activity is increased
upon HFD (Bai et al., 2011), likely favouring fat storage over burning (Erener et al., 2012).
Consistent with this, PARP-1 activity was found to enhance adipogenesis (Erener et al.,
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2012). Oppositely, PARP activity was decreased in muscle upon fasting (Bai et al., 2011),
when lipid oxidation is favored. Collectively, this indicates that physiological changes in
PARP-1 activity might help balancing whole-body energy metabolism
Paribs improve oxidative capacity in worm and human models of reduced mitochondrial
function
To elucidate whether Paribs could recover mitochondrial function in models with genetically
determined mitochondrial defects, we first used the C. elegans mev-1 strain, which contains
a missense mutation in cyt-1, the worm homolog of mammalian succinate dehydrogenase
cytochrome b, a component of complex II (Senoo-Matsuda et al., 2001). The ability of
complex II to catalyse electron transport from succinate to ubiquinone is compromised in
mev-1 mutants, leading to increased superoxide levels and premature aging. MRL-45696
effectively inhibited PARP activity (Figure 4C) and OCR in mev-1 mutants (Figure 4D), as
previously noticed in wild-type worms using other Paribs (Mouchiroud et al., 2013). The
increased respiration also translated into effective prevention against age-related
physiological decline, as old mev-1 mutants maintained youthful motility (Figure 4E).
To test whether these observations could also apply in human models, we used skin
fibroblasts from a patient with a mutation in the nuclear NDUFS1 gene, which reduced
complex I activity by 87% (Bugiani et al., 2004). MRL-45696 efficiently prevented H2O2-
induced PARP activation (Figure 4F) and increased NAD+ (Figure 4G) in NDUFS1 mutant
fibroblasts. In line with observations in mouse tissues, MRL-45696 also increased OCR
(Figures 4H–4J), lipid oxidation and CS activity in these cells, testifying for enhanced
mitochondrial function.
Finally, we evaluated whether Paribs could improve acquired defects in mitochondrial
function, such as the decreased mitochondrial activity observed in skeletal muscle cells of
obese humans (Patti and Corvera, 2010). MRL-45696 effectively abrogated PARP
activation, enhanced NAD+ levels (Figures 4K and 4L) and stimulated OCR (Figure 4M) in
primary myotubes from obese patients (Timmers et al., 2012). In addition, MRL-45696
granted a higher ability to oxidize lipids (Figure 4N), probably by enhancing mitochondrial
function, as suggested by the higher CS activity (Figure 4O). Our data therefore illustrate
that Paribs enhance mitochondrial function in both acquired and genetically determined
mitochondrial alterations. Hence, the interrelation between PARP activity and mitochondrial
function is well conserved across the evolutionary spectrum from worms to mice and
humans.
In sum, this work provides evidence that drugs used at present in the cancer field could be
retooled to treat metabolic dysfunction linked to impaired mitochondrial activity, even in a
long-term fashion. Paribs are currently being tested for oncology indications, with positive
outcomes in tumors with dysfunctional homologous DNA recombination repair (Curtin and
Szabo, 2013). The success of Paribs is thought to rely on the high dependency of these
cancer cells on PARP enzymes for DNA repair (Curtin and Szabo, 2013), but could also
involve their capacity to reprogram cells towards oxidative metabolism (Bai et al., 2011).
Notably, Paribs are in general well tolerated by patients with few reported side effects
(Audeh et al., 2010; Bundred et al., 2013; Tutt et al., 2010). Within the time-frame of this
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study, and in line with findings in Parp-1−/− mice (Bai et al., 2011) and in patients treated
with Olaparib (Audeh et al., 2010; Bundred et al., 2013; Tutt et al., 2010), no toxicity or
genomic instability was seen in MRL-45696-treated mice. In contrast, marked metabolic
effects were observed, such as improved mitochondrial function and protection against diet-
induced obesity. Importantly, PARP inhibition rescued mitochondrial activity in situations
of genetically determined mitochondrial dysfunction. Therefore, our results open the path of
using Paribs to improve invalidating diseases caused by impaired mitochondrial function.
While this could also set the stage for Paribs to impinge on other metabolic complex
diseases, such as seen during type 2 diabetes, further work must be done to ensure the safety
and feasibility of these treatments in non-life threatening diseases.
EXPERIMENTAL PROCEDURES
Materials
BSI-201, ABT-888 and AZD-2281 were purchased from Selleck Chemicals and PJ-34 from
Sigma. MRL-45696, kindly provided by Thomas Vogt from Merck Research Laboratories,
is closely related to the potent Parib, niraparib or 2-phenyl-2H-indazole-7-carboxamide
(Jones et al., 2009). MRL-45696 is a dual PARP-1/2 inhibitor with IC50 of 0.8 and 0.3nM,
respectively. In contrast, it displays an IC50 in the micromolar range against PARP-3,
vPARP, and Tankyrase. C2C12 cells were obtained from ATCC. Myoblasts from obese
patients and NDUFS1 mutant fibroblasts were provided by Drs. Schrauwen (Timmers et al.,
2012) and Zeviani (Bugiani et al., 2004).
Cell culture and molecular biology studies
Methods for cellular and molecular assays are provided in the Supplemental Procedures.
In vivo and ex vivo studies
To compare administration routes, male C57BL/6J mice were given MRL-45696 by gavage
or food admix at a dose of 50 mg/kg/d for 5 days. Mice were sacrificed either 6hr after the
last gavage or in the random fed state, respectively. MRL-45696 concentration in plasma
and muscle was measured by mass spectrometry. For the long-term animal studies, 10-
week-old male C57BL/6J mice (Charles River) or SIRT1skm−/− mice were fed pellets
containing either vehicle and/or PARP inhibitor (50 mg/g/kg) for 18wks. The generation of
SIRT1skm−/− mice is described in the Supplemental Procedures. During the experiment,
mice were housed under a 12hr dark-light cycle and had ad libitum access to water and food.
Clinical tests were carried out according to standard operational procedures (SOPs).
Mitochondrial function in permeabilized EDL muscle fibers was evaluated using the
Oxygraph-2k respirometer (Oroboros, Austria). Correlations in the BXD mouse genetic
reference population were identified using the GeneNetwork database (http://
www.genenetwork.org). Details are in the Supplemental Procedures.
C. elegans studies
Worm strains were cultured at 20°C on nematode growth media agar plates seeded with E.
coli strain OP50. Mev-1(kn1) mutant worms were provided by the Caenorhabditis Genetics
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Center (University of Minnesota). Protocols used for western blotting and worm
phenotyping are described in the Supplemental Procedures.
Statistical methods
Statistical analyses were performed with Prism software (GraphPad). Differences between
two groups were analysed using Student’s t-test (two-tailed) and multiple comparisons were
analyzed by ANOVA with a Bonferroni post-hoc test. A p value less than 0.05 was
considered significant. Data are expressed as means±SEM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Inhibition of poly(ADP-ribose) polymerases enhances endurance performance
• Inhibition of PARPs improves mitochondrial function in skeletal muscle
• Parp-1 correlates with energy expenditure in heterogeneous mouse populations
• Genetic and acquired mitochondrial defects can be rescued by PARP inhibition
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Figure 1. Paribs protect from HFD-induced metabolic complications
Ten-wk-old male C57Bl/6J mice were challenged with HFD supplemented with either
vehicle (DMSO; Veh) or MRL-45696 (50 mg/kg/day) (n=10/group). (A) Body weight gain
during 18wks of HFD. (B) Fat mass was measured using Echo-MRI. (C–D) A
comprehensive laboratory animal monitoring system was used to evaluate VO2 (C) and
activity (D) after 7wks of HFD. (E) Food intake measured by averaging weekly food
consumption during HFD. (F) Liver 8-oxo-dG content, as indicator of DNA damage, (G)
muscle lipid peroxidation-derived aldehyde, 4-hydroxy-2-nonenal, and (H) muscle total
poly(ADP-ribose) (PAR) contents were measured in vehicle and MRL-45696-treated mice
(n=7/group) (I–J) Total intracellular (I) and mitochondrial (J) NAD+ levels in
gastrocnemius of refed vehicle and MRL-45696-treated mice (n=5–10/group). (K) SIRT1,
acetylated FOXO1 and total FOXO1 protein levels were assessed in total homogenates from
quadriceps of chow-diet fed mice. (L) The acetylation status of Ndufa9 immunoprecipates
was tested as a marker of SIRT3 activity. Values are shown as mean+/−SEM. * indicates
statistical significant difference vs. respective Veh group. *, p<0.05; **, p<0.01; ***,
p<0.001. This figure is complemented by Figures S1 and S2, and Table S1.
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Figure 2. Paribs enhance exercise capacity and muscle mitochondrial function
Chow fed male C57BL/6J and congenic SIRT1skm−/− mice (n=5–10/group) treated with
either vehicle (DMSO; Veh) and/or MRL-45696 (50 mg/kg/day) were subjected to (A)
endurance treadmill test after 13wks treatments, (B) respirometry analysis of permeabilized
EDL muscle fibers (CI, complex I; CII, complex II; ETS, electron transport system) and (C)
CS activity measurement. (D) Oleic acid oxidation rate in the muscles of Veh and
MRL-45696-treated mice after 18wks treatment (n=5–7/group). (E) Mitochondria DNA
abundance in quadriceps of Veh and MRL-45696-treated mice (n=8/group). Results are
expressed as mitochondrial DNA amount (16S) relative to genomic DNA (UCP2). (F)
Cytochrome c oxidase (COX), succinate dehydrogenase (SDH) staining in gastrocnemius of
Veh and MRL-45696-treated mice. Soleus is indicated by an arrow. (G) Protein levels of
MHCI and IIb were evaluated, using heat shock protein 90 (Hsp90) as loading control (H)
Myosin heavy chain I staining (MHCI) of gastrocnemius of Veh and MRL-45696-treated
mice. Values are shown as mean+/−SEM. * indicates statistical significant difference vs.
respective Veh group. *, p<0.05; **, p<0.01; ***, p<0.001. This figure is complemented by
Figure S3.
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Figure 3. Paribs induce UPRmt in muscle by increasing mitochondrial protein translation
(A) Blue-Native Page using isolated mitochondria from quadriceps of vehicle (DMSO; Veh)
and MRL-45696 treated mice. A non-specific band was used as loading control. (B)
Mitochondrial and (C) cytosolic protein translation measured in MEFs after 100nM
MRL-45696 treatment for 40hr. (D) Quantification of protein translation rates. (E) MTCOI,
SDHA, ClpP and Hsp60 protein levels were evaluated in quadriceps from Veh and
MRL-45696 mice, using tubulin as a loading control. (F) Quantification of mitonuclear and
UPRmt markers. *, p<0.05 and ***<0.001. This figure is complemented by Figure S4.
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Figure 4. Parp activity negatively correlates with energy expenditure in mouse populations and
its inhibition improves mitochondrial function in worm and human models of mitochondria
dysfunction
(A) Expression of Parp-1 in the quadriceps of 37 strains of BXD mice. Each bar represents
mRNA from a pool of ~5 animals per strain. Extreme strains and the parental strains are
labelled. (B) Top: Correlation between quadriceps muscle Parp-1 expression and
phenotypes collected from BXD mice. Night VO2 was measured though indirect
calorimetry. VO2 improvement represents the increase in VO2max after 10 days of
voluntary exercise. Bottom: Correlation between quadriceps muscle Parp-1 and muscle fiber
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type genes in the same dataset. (C) Total PAR content at day 2 of adulthood (n=~500
worms/sample) in mev-1(kn1) complex II-deficient C. elegans after water and 100nM
MRL-45696 treatment. (D) Respiration at day 3 (n=10 worms/well, 19 wells/group) and (E)
movement at day 1, 3 and 5 of adulthood (n=37–90 worms/group). (F) H2O2 (500µM)-
induced PARylation after 48hr pretreatment with either vehicle (Veh) or 100nM
MRL-45696 in NDUFS1 mutant human fibroblasts. (G–J) NAD+ levels (G), O2
consumption rates (H), oleic acid oxidation (I) and CS activity (J) in human NDUFS1
mutant fibroblasts after Veh and 100nM MRL-45696 for 48hr (n=3–12 samples/group). (K)
H2O2 (500µM)-induced PAR content after 24hr pretreatment with either Veh or 10nM
MRL-45696 in human primary myotubes. (L–O) NAD+ levels (L), O2 consumption rates
(M), oleic acid oxidation (N) and CS activity (O) in human primary myotubes after Veh or
10nM MRL-45696 treatment for 72hr (n=6–12 samples/group). * indicates statistical
significant difference vs. respective Veh group. *, p<0.05; **, p<0.01; ***, p<0.001.
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